<- Back to digest

JOA - 2026-11-06 - Journal Article

Concurrent Selective Serotonin Reuptake Inhibitor and Factor Xa Inhibitor Use Is Associated With Increased Transfusion and Periprosthetic Joint Infection After Primary Total Hip Arthroplasty Despite Tranexamic Acid.

Rice SW, Mehta S, Hall RR, Proffitt EB, Ayers DC

database studyLOE IIIn = N not explicitly stated in abstract; large EHR database with multiple 1:1 propensity-score matched cohorts30, 90, and 365 days

Topics

arthroplasty
PMID: 42994649DOI: 10.1016/j.arth.2026.11.019View on PubMed ->

Key Takeaway

Preoperative SSRI use—not concurrent FXa inhibitor use—drives elevated transfusion (RR 1.44 at 30 days), PJI (RR 1.48 at 1 year), and revision THA (RR 1.84 at 1 year) rates after primary THA despite universal TXA use.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This study evaluated whether concurrent SSRI and FXa inhibitor use compounded bleeding and complication risk versus either agent alone in primary THA patients receiving TXA, using propensity-score matched cohorts from a large EHR database. SSRI-only use was independently associated with higher transfusion (30-day RR 1.44), PJI (1-year RR 1.48), and revision THA (1-year RR 1.84) versus matched controls, while FXa-only use showed no significant increase in any outcome. Concurrent use exceeded FXa-only rates for transfusion (RR 1.54–2.12) and 90-day/1-year PJI and revision, but did not differ significantly from SSRI-only use, implicating SSRI-mediated platelet dysfunction as the primary driver.

Key Limitation

The EHR database design cannot confirm whether SSRIs were continued perioperatively or held, making it impossible to determine whether the observed risk is modifiable by preoperative SSRI discontinuation.

Original Abstract

BACKGROUND

Selective serotonin reuptake inhibitors (SSRIs) impair platelet function, and concurrent SSRI and oral anticoagulant use has been associated with major bleeding in medical populations. We evaluated whether preoperative concurrent SSRI and factor Xa (FXa) inhibitor use was associated with higher transfusion and complication rates compared with use of either medication alone after primary total hip arthroplasty (THA) when tranexamic acid (TXA) use was standard.

METHODS

Adult patients who underwent primary THA and received TXA on the day of surgery were identified in a large electronic health records database. The SSRI-only, FXa-only, and concurrent-use cohorts were independently 1:1 propensity-score matched to controls who did not have either exposure. The concurrent-use cohort was also matched directly to the SSRI-only and FXa-only cohorts. The primary outcome was allogeneic red blood cell transfusion. The secondary outcomes were surgical site infection (SSI), venous thromboembolism (VTE), periprosthetic joint infection (PJI), and revision THA at 30, 90, and 365 days.

RESULTS

Compared with matched controls, SSRI-only patients had significantly higher transfusion, PJI, and revision THA rates at all timepoints (30-day transfusion risk ratio [RR] 1.44; 1-year PJI, RR 1.48; 1-year revision, RR 1.84; all P < 0.001). The FXa-only patients did not have higher transfusion or complication rates. Compared with SSRI-only patients, concurrent use was not associated with significantly different rates of any outcome at any timepoint. Compared with FXa-only use, concurrent use was associated with higher transfusion rates at all timepoints and higher PJI and revision rates at 90 days and one year (RR 1.54 to 2.12; all P ≤ 0.026).

CONCLUSION

Preoperative SSRI use was associated with higher transfusion, PJI, and revision THA rates. Concurrent use exceeded FXa-only rates, but not SSRI-only rates, suggesting that SSRI use may be the more important perioperative risk marker. The use of SSRIs should be recognized during preoperative bleeding-risk assessment.